Distribution of Growth Hormone-releasing Hormone-like Immunoreactivity in Human Tissue Extracts
Overview
Affiliations
A specific RIA for human pancreatic tumor GH-releasing hormone [hpGRH(1-44)NH2] was developed using an antiserum which recognizes the region (Met27-Leu44)NH2 of hpGRH(1-44)NH2. This RIA was used to measure GH-releasing hormone-like immunoreactivity (GRH-LI) in various human tissue extracts. The highest concentration of GRH-LI was detected in extract of pituitary stalk with moderate amounts found in hypothalamus and optic chiasm but none in the cerebrum, cerebellum, medulla oblongata, spinal cord, and anterior pituitary. In peripheral organs appreciable quantities of GRH-LI were found in the pancreas, whereas extracts of thyroid, lung, stomach, duodenum, ileum, colon, adrenal, and kidney contained very low concentrations of GRH-LI. No GRH-LI was detected in liver and spleen extracts. Gel permeation chromatographic analysis of the tissue extract from the hypothalamus revealed only one peak which eluted at the same position as that of 125I-hpGRH(1-44)NH2. Similar analysis of an extract from the optic chiasm showed one peak at the same position as that of 125I-hpGRH(1-44)NH2 and another peak which eluted after hpGRH(1-44)NH2. In contrast, an extract from the pancreas contained only one peak which eluted before 125I-hpGRH(1-44)NH2, indicating a possible precursor form of hpGRH(1-44)NH2. Limited trypsin digestion of the GRH-LI material from the pancreas, followed by gel permeation chromatographic analysis, yielded a major peak eluting at the same position as that of 125I-hpGRH(1-44)NH2. These results suggest that the GRH-LI detected in the hypothalamus most likely corresponds to hpGRH(1-44)NH2 in structure and that the GRH biosynthesized in the hypothalamus is transported to the stalk median eminence and stored there for release into the portal vessels.
Effects of GHRH and its analogues on the Vascular System.
Yu H, Peng H Rev Endocr Metab Disord. 2024; .
PMID: 39570567 DOI: 10.1007/s11154-024-09932-7.
Munoz-Moreno L, Roman I, Bajo A Rev Endocr Metab Disord. 2024; .
PMID: 39505776 DOI: 10.1007/s11154-024-09922-9.
miR-449a contributes to glucocorticoid-induced CRF-R1 downregulation in the pituitary during stress.
Nemoto T, Mano A, Shibasaki T Mol Endocrinol. 2013; 27(10):1593-602.
PMID: 23893957 PMC: 5427883. DOI: 10.1210/me.2012-1357.
Sugihara H, Shibasaki T, Tatsuguchi A, Okajima F, Wakita S, Nakajima Y J Endocrinol Invest. 2007; 30(5):421-7.
PMID: 17598976 DOI: 10.1007/BF03346321.
Growth Hormone Releasing Hormone (GHRH) and the GHRH Receptor.
Lin-Su K, Wajnrajch M Rev Endocr Metab Disord. 2002; 3(4):313-23.
PMID: 12424433 DOI: 10.1023/a:1020949507265.